PE20010685A1 - COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE - Google Patents

COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE

Info

Publication number
PE20010685A1
PE20010685A1 PE2000000942A PE0009422000A PE20010685A1 PE 20010685 A1 PE20010685 A1 PE 20010685A1 PE 2000000942 A PE2000000942 A PE 2000000942A PE 0009422000 A PE0009422000 A PE 0009422000A PE 20010685 A1 PE20010685 A1 PE 20010685A1
Authority
PE
Peru
Prior art keywords
interleuquin
release
processing
urea
hydroxy
Prior art date
Application number
PE2000000942A
Other languages
Spanish (es)
Inventor
Mark Anthony Dombroski
Bruce Henry Littman
Thasia Louise Goodwin Woodworth
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20010685A1 publication Critical patent/PE20010685A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A USO DE UNA COMPOSICION QUE COMPRENDE: a)UN POLIPEPTIDO ANTAGONISTA DEL RECEPTOR DE INTERLEUQUINA 1 (IL-1ra), DE PREFERENCIA DE UNA SECUENCIA (ID SEQ N°2) DE 169 AMINOACIDOS; b)UN AGENTE NO ESTEROIDEO QUE INHIBE EL PROCESAMIENTO Y LA LIBERACION DE IL-1 TAL COMO DIARILSULFONILUREA R1-(O=)S(=O)-NH-C(=O)-NH-R2; DONDE R1 Y R2 SON UN GRUPO DE FORMULA II EN LA QUE LAS LINEAS --- REPRESENTAN DOBLES ENLACES OPCIONALES; n ES 0-3; A, B, D, E Y G SON O, S, N, CR5R6; R5 Y R6 SON H, ALQUILO C1-C6, HALOGENO, CIANO, AMINO, OH, ENTRE OTROS, SIENDO COMPUESTOS SELECCIONADOS 1-(1,2,3,5,6,7-HEXAHIDRO-s-INDACEN-4-IL)-3-[4-(1-HIDROXI-1-METIL-ETIL)-FURANO-2-SULFONIL]-UREA, 1-(2,6-DIISOPROPIL-FENIL)-3-[4-(1-HIDROXI-1-METIL-ETIL-FURANO-2-SULFONIL]-UREA, 1-(4-CLORO-2,6-DIISOPROPIL-FENIL)-3-[3-(HIDROXI-1-METIL-ETIL)-BENCENOSULFONIL]-UREA, ENTRE OTROS. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS INFLAMATORIOS TAL COMO ARTRITIS REUMATOIDE, OSTEOARTRITIS, ASMA, NEURODEGENERACION, ENTRE OTROSIT REFERS TO THE USE OF A COMPOSITION THAT INCLUDES: a) AN ANTAGONIST POLYPEPTIDE OF THE INTERLEUQUIN 1 RECEPTOR (IL-1ra), OF PREFERENCE OF A SEQUENCE (ID SEQ N ° 2) OF 169 AMINO ACIDS; b) A NON-STEROID AGENT THAT INHIBITS THE PROCESSING AND RELEASE OF IL-1 SUCH AS DIARYLSULFONYLUREA R1- (O =) S (= O) -NH-C (= O) -NH-R2; WHERE R1 AND R2 ARE A GROUP OF FORMULA II IN WHICH THE LINES --- REPRESENT DOUBLE OPTIONAL LINKS; n IS 0-3; A, B, D, E, and G ARE O, S, N, CR5R6; R5 AND R6 ARE H, C1-C6 ALKYL, HALOGEN, CYANE, AMINO, OH, AMONG OTHERS, BEING SELECTED COMPOUNDS 1- (1,2,3,5,6,7-HEXAHIDRO-s-INDACEN-4-IL) -3- [4- (1-HYDROXY-1-METHYL-ETHYL) -FURANO-2-SULFONIL] -UREA, 1- (2,6-DIISOPROPYL-PHENYL) -3- [4- (1-HYDROXY-1 -MEthyl-ETHYL-FURANE-2-SULFONIL] -UREA, 1- (4-CHLORO-2,6-DIISOPROPYL-PHENYL) -3- [3- (HYDROXY-1-METHYL-ETHYL) -BENZENOSULFONIL] -UREA, AMONG OTHERS, THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF INFLAMMATORY DISORDERS SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, ASTHMA, NEURODEGENERATION, AMONG OTHERS

PE2000000942A 1999-09-14 2000-09-12 COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE PE20010685A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
PE20010685A1 true PE20010685A1 (en) 2001-07-03

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000942A PE20010685A1 (en) 1999-09-14 2000-09-12 COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE

Country Status (13)

Country Link
EP (1) EP1214087A1 (en)
JP (1) JP2003509378A (en)
AR (1) AR033650A1 (en)
AU (1) AU6464400A (en)
BR (1) BR0014003A (en)
CA (1) CA2383026A1 (en)
CO (1) CO5190701A1 (en)
EC (1) ECSP003652A (en)
GT (1) GT200000155A (en)
PA (1) PA8502901A1 (en)
PE (1) PE20010685A1 (en)
TN (1) TNSN00183A1 (en)
WO (1) WO2001019390A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1729810B1 (en) 2004-04-02 2018-08-15 Swedish Orphan Biovitrum AB (Publ) Methods of reducing aggregation of il-1ra
WO2008129288A2 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
US10538487B2 (en) 2015-02-16 2020-01-21 The University Of Queensland Sulfonylureas and related compounds and use of same
WO2017140778A1 (en) 2016-02-16 2017-08-24 The University Of Queensland Sulfonylureas and related compounds and use of same
EP3445757B1 (en) 2016-04-18 2020-11-25 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
EP3851434A1 (en) 2017-01-23 2021-07-21 Genentech, Inc. Chemical compounds as inhibitors of interleukin-1 activity
CA3059458A1 (en) 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
WO2018225018A1 (en) 2017-06-09 2018-12-13 Cadila Healthcare Limited Novel substituted sulfoximine compounds
US11370776B2 (en) 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
AU2018297606B2 (en) 2017-07-07 2022-08-11 Inflazome Limited Novel sulfonamide carboxamide compounds
CN117143042A (en) 2017-07-24 2023-12-01 诺华股份有限公司 Compounds and compositions for treating disorders associated with NLRP activity
SG11202001166RA (en) * 2017-08-15 2020-03-30 Inflazome Ltd Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668842A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited Novel substituted sulfonylurea derivatives
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
EP3759103A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
WO2020010143A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Nlrp modulators
BR112021001012A2 (en) 2018-07-20 2021-04-20 F. Hoffmann-La Roche Ag sulfonylurea compounds as inhibitors of interleukin-1 activity
WO2020086732A1 (en) 2018-10-24 2020-04-30 Novartis Inflammasome Research, Inc. Compounds and compositions for treating conditions associated with nlrp activity
AU2020210117A1 (en) 2019-01-14 2021-08-05 Zydus Lifesciences Limited Novel substituted sulfonylurea derivatives
EP4157860A4 (en) * 2020-05-25 2024-03-06 Beijing Vdjbio Co Ltd An interleukin-1 receptor antagonist and a fusion protein containing the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DK1270565T3 (en) * 1997-01-29 2004-10-04 Pfizer 4-substituted furan-2-sulfonamide and its use in the preparation of sulfonylurea derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (en) * 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins

Also Published As

Publication number Publication date
PA8502901A1 (en) 2002-02-21
GT200000155A (en) 2002-03-08
EP1214087A1 (en) 2002-06-19
BR0014003A (en) 2002-05-21
CA2383026A1 (en) 2001-03-22
ECSP003652A (en) 2002-04-23
CO5190701A1 (en) 2002-08-29
AU6464400A (en) 2001-04-17
AR033650A1 (en) 2004-01-07
WO2001019390A1 (en) 2001-03-22
TNSN00183A1 (en) 2005-11-10
JP2003509378A (en) 2003-03-11

Similar Documents

Publication Publication Date Title
PE20010685A1 (en) COMPOSITION INCLUDING AN INTERLEUQUIN 1 RECEPTOR ANTAGONIST POLYPEPTIDE AND A DIARYLSULPHONYLUREA AS AN INHIBITOR OF IL-1 PROCESSING AND RELEASE
PE20040840A1 (en) 4-OXOQUINOLINE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE
HRP941000B9 (en) Morpholine and thiomorpholine tachykinin receptor antagonists
ES2161231T3 (en) HETEROCICLICAL COMPOUNDS AS AN ANTIGONIST OF BRADIQUININA.
AR038563A1 (en) ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
PE20060298A1 (en) BENZHIMIDAZOLONE CARBOXYL ACID DERIVATIVES
MX2007013065A (en) Dihydrobenzofuran derivatives and uses thereof.
ATE420644T1 (en) CONDENSED AZABICYCLIC COMPOUNDS AS INHIBITORS OF THE VANILLOID RECEPTOR 1 (VR1)
PT1716152E (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
DE602004012858D1 (en) 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS
ATE469892T1 (en) SUBSTITUTED 1H-DIHYDROPYRAZOLES, THEIR PREPARATION AND USE
UY27976A1 (en) HETEROCYCLIC PIPERAZINES SUBSTITUTED FOR THE TREATMENT OF CHICHOPHRENIA
NO20063470L (en) Tetrazole compounds and their use of metabotrophic glutamate receptor antagonists
PE20040650A1 (en) GLUCOCORTICOID RECEPTOR MODULATORS
BRPI0413305A (en) fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 receptor (vr1)
DE602006007556D1 (en) HETEROARYLSULFONYL STILENE AS 5-HT2A ANTAGONISTS
BR0007595A (en) 4- (heterocyclisulfonamido) -5-methoxy-6- (2-methoxyphenoxide) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
AR028824A1 (en) NPY-5 ANTAGONIST COMPOUNDS AND ITS USE IN THE MANUFACTURE OF MEDICINES.
NO20061981L (en) Arylindenopyridines and arylindenopyridines and their use as adenosine A2A receptor agonist
PE20030872A1 (en) PHARMACEUTICAL COMPOSITION OF THE 5HT4 TEGASEROD PARTIAL AGONIST
ATE374190T1 (en) TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS
PE16299A1 (en) 2-IMIDAZOLINYLAMINOINDOL COMPOUNDS USEFUL AS ALPHA-2 ADRENORECEPTOR AGONISTS
NO20080323L (en) Compounds and their salts specific to PPAR receptors and EGF receptors and their use in medicine
PL374019A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
BR0211761A (en) depsipeptides and processes for preparing them

Legal Events

Date Code Title Description
FC Refusal